In recent days, UiPath has drawn fresh attention as easing geopolitical tensions and a friendlier backdrop for technology spending have supported renewed interest in AI automation platforms, including ...

In early January 2026, UiPath Inc. was added to the S&P 1000 and S&P MidCap 400 indices after reporting earnings that exceeded expectations and highlighting its progress in blending AI with robotic ...

Palantir has been one of the best growth stories in the market. UiPath is just beginning to see its revenue growth accelerate as it looks to become an AI agent orchestration platform. UIPath's ...

PATH is transitioning from an RPA provider to a leading agent AI platform, underpinned by strategic partnerships with Snowflake, Google, Microsoft, and Nvidia. PATH possesses every capability to take ...

UiPath Inc. (NYSE: PATH) stock jumped in Wednesday's extended trading after the company released its third quarter earnings report, beating expectations on the top and bottom lines. Here's a look at ...

About The Study: During 2012 to 2023, the prevalence of injecting methamphetamine only or both methamphetamine and opioids increased significantly among people who inject drugs entering treatment, ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

A new proof-of-concept attack shows that malicious Model Context Protocol servers can inject JavaScript into Cursor’s browser — and potentially leverage the IDE’s privileges to perform system tasks.

UiPath is positioning itself as the bridge connecting humans, systems, and AI. The company has narrowed losses and is approaching profitability. The long-term growth runway is large. 10 stocks we like ...

Note that some links may require registration or subscription. The practice of "bluetoothing," when users inject the blood of already intoxicated individuals, is contributing to global HIV spikes.